SYNDEVRX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.syndevrx.com
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1
Recruiting
- Conditions
- HR+/HER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- SynDevRx, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05455619
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸Miami Cancer Institute at Baptist Health, Miami, Florida, United States
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsNeoplasmAdvanced MalignancyMetastasis
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- SynDevRx, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02743637
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath